3rd Quarter - Report
LOPER CONSULTING LLC for TEVA PHARMACEUTICALS USA
Firm
Client
Income
$51,000
Expenses
—
What was lobbied
One issue area, each in the filer's own words, with who lobbied on it and where.
Health Issues HCR
H.R. 6433, the "FDA User Fee Corrections Act of 2012," which amends the Food and Drug Administration Safety and Innovation Act (Public Law 112-144) to make technical changes to both the generic drug user fee program and the medical device user fee program; Monitoring the impact of sequestration on FDA funding Monitoring supply chain safety
| Lobbyist | Covered position, as disclosed |
|---|---|
| GINGER LOPER | Special Assistant to the President (2002-2005) |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.